- Ariad Pharmaceuticals (ARIA) collapses 59% after the company says that it's suspending the enrollment of new patients in trials for its Iclusig treatment for chronic myeloid leukemia.
- The pause follows an increase in the rate of cardiac problems in patients who received Iclusig.
- Pending FDA approval, Ariad hopes to resume enrollment with lower doses of the drug. Patients already on the medicine will continue to do so but with smaller doses.
- The U.S. prescribing information for Iclusig remains unchanged. (PR)
Ariad shares plunge after it pauses enrollment for leukemia drug trial
From other sites
at 4-traders.com (Mon, 1:45AM)
at Nasdaq.com (Mar 25, 2015)
at Nasdaq.com (Feb 26, 2015)
at Benzinga.com (Feb 20, 2015)
at Nasdaq.com (Jan 23, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs